Abstract

BackgroundRP1 is a novel, enhanced potency, oncolytic version of HSV-1 engineered to express human GM-CSF and GALV-GP R-.1 RP1 + anti-PD1 therapy combination has resulted in deep and durable responses,...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Abstract CT155: Clinical biomarker studies with an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced solid tumors indicates potent immune activation
Kevin J Harrington ... Henry Castro
American Journal of Cancer | VOL. 82
Kevin J Harrington, et. al.Kevin J Harrington ... Henry Castro
15 Jun 2022
Abstract LB180: Clinical biomarker studies with two fusion-enhanced versions of oncolytic HSV (RP1 and RP2) alone and in combination with nivolumab in cancer patients indicate potent immune activation
Kevin J Harrington ...
American Journal of Cancer | VOL. 81
Kevin J Harrington, et. al.Kevin J Harrington ...
01 Jul 2021
Co-expression of PD-L1 and DDR2 in cervical cancer
Whitney Grither ... Premal Thaker
Gynecologic oncology | VOL. 162
Whitney Grither, et. al.Whitney Grither ... Premal Thaker
01 Aug 2021
Abstract 3814: A pan cancer analysis of the tumor inflammation signature
Patrick Danaher ... Alessandra Cesano
American Journal of Cancer | VOL. 77
Patrick Danaher, et. al.Patrick Danaher ... Alessandra Cesano
01 Jul 2017
View more papers

More From: Journal for ImmunoTherapy of Cancer

Paper Title
Journal
Date
Author
Assessing the implications of sentinel lymph node removal in cervical cancer: an immunogenetic perspective – a SENTICOL ancillary study
Gaurav Thareja ... Alejandra Martinez
Journal for ImmunoTherapy of Cancer | VOL. 12
Gaurav Thareja, et. al.Gaurav Thareja ... Alejandra Martinez
15 Jul 2024
Novel insights into paclitaxel’s role on tumor-associated macrophages in enhancing PD-1 blockade in breast cancer treatment
Yoonjeong Choi ... In-San Kim
Journal for ImmunoTherapy of Cancer | VOL. 12
Yoonjeong Choi, et. al.Yoonjeong Choi ... In-San Kim
15 Jul 2024
Cantharidin overcomes IL-2Rα signaling-mediated vorinostat resistance in cutaneous T-cell lymphoma through reactive oxygen species
Man Zhu ... Yanmin Zhang
Journal for ImmunoTherapy of Cancer | VOL. 12
Man Zhu, et. al.Man Zhu ... Yanmin Zhang
14 Jul 2024
A crisis in clinical research
David S Hong ... Mario Sznol
Journal for ImmunoTherapy of Cancer | VOL. 12
David S Hong, et. al.David S Hong ... Mario Sznol
11 Jul 2024
View more papers